


Results Update
 21 July 2023
BUY

Share Price: SEK45.1

Target Price: SEK109.0 (112.0)

Hansa Biopharma

Accelerating sales and news flow in H2(23e)

Research analysts:

Erik Hultgård
+46 8 5886 92 37
erik.hultgard@carnegie.se

Ulrik Trattner
+46 8 5886 8589
ulrik.trattner@carnegie.se

Record Idefirix sales in Q2 but costs higher than expected

Idefirix sales were SEK30m in Q2, up from SEK14m in Q1 and 50% above our SEK20m estimate. Total revenues amounted to SEK37m versus our SEK30m estimate. The operating loss was SEK229m for the quarter versus our SEK178m estimate due to higher costs from clinical development, inflation, and FX. In the US registrational study, 76 patients have been enrolled, and enrolment continues to randomise a total of 64 patients. Hansa still targets complete randomisation in H2(23). Enrolment has been completed in the Ph I trial with next generation IgG cleaving enzyme HNSA5487 designed to enable repeat dosing.

Germany and the UK to drive acceleration in sales in H2(23e)

We raise cost estimates following Q2, while Idefirix assumptions are left unchanged. We are growing increasingly confident that we are at or close to an inflection point in the uptake of Idefirix in Europe. Pricing and reimbursement have now been secured in 13 EU countries, including the top five markets. Following the publication of ESOT guidelines last year, national guidelines have recently been implemented in key markets and a new Eurotransplant programme to enable allocation of organs also to highly sensitised patients was implemented in June. We anticipate that these changes should accelerate the uptake during H2(23.) We are also encouraged by the recent approval of Idefirix in Australia, covering both deceased and living donors, which should contribute to growth from H1(23e) when access is secured.

News flow intensifying in H2(23) – large upside potential if management delivers

Hansa expects top-line results from the Ph II study in GBS, full Ph II AMR data and 5-year data in kidney transplantation in H2. We think the data read outs will be important to add confidence in the long-term potential of Idefirix and the technology platform. After years of disappointing progress with both the uptake of Idefirix and with clinical development, we see significant upside potential in the stock should management deliver on the expected uptake and news flow in H2(23). We reiterate BUY but trim our SOTP-based TP to SEK109 (112).


Changes in this report

	From	To	Chg
EPS adj. 2023e	-13.18	-15.11	-15%
EPS adj. 2024e	-7.85	-9.39	-20%
EPS adj. 2025e	-5.38	-6.96	-29%

Upcoming events**Key facts**

No. shares (m)	55.0
Market cap. (USDm)	240
Market cap. (SEKm)	2,480
Net IB Debt. (SEKm)	131
Adjustments (SEKm)	0
EV (2023e) (SEKm)	2,611
Free float	100.0%
Avg. daily vol. ('000)	136
Risk	High Risk
Fiscal year end	December
Share price as of (CET)	20 Jul 2023 17:29

Key figures (SEK)	2022	2023e	2024e	2025e
Sales	154	173	381	608
EBITDA	-584	-781	-611	-440
EBIT	-587	-783	-614	-443
EPS	-12.23	-15.11	-9.39	-6.96
EPS adj.	-12.23	-15.11	-9.39	-6.96
DPS	0.00	0.00	0.00	0.00
Sales growth Y/Y	356%	12%	120%	60%
EPS adj. growth Y/Y	+chg	-chg	+chg	+chg
EBIT margin	-380.1%	-453.0%	-161.1%	-72.8%
P/E adj.	n.m.	n.m.	n.m.	n.m.
EV/EBIT	neg.	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.	neg.
P/BV	4.1	neg.	neg.	neg.
Dividend yield	0.0%	0.0%	0.0%	0.0%
FCF yield	-21.2%	-34.6%	-20.7%	-15.3%
Equity/Total Assets	35.9%	-27.1%	-234.0%	342.7%
ROCE	-53.3%	-82.7%	n.m.	188.8%
ROE adj.	-89.3%	-437.4%	106.7%	41.0%
Net IB debt/EBITDA	1.3	-0.2	-1.2	-2.9

Share price -5Y

High/Low (12M)	SEK90.7/41.7			
Perf.	3M	6M	12M	YTD
Abs.	-1.3	-36.5	-54.2	-8.5
Rel.	0.7	-35.5	-60.8	-14.6

Source: Carnegie Research, FactSet, Millstream & company data

Performance & valuation

Price relative to market – 1Y



— Hansa Biopharma
— OMX Stockholm PI (Se)

Source: FactSet


Price relative to sector – 1Y



— Hansa Biopharma
— Healthcare

Source: FactSet


Adj. EPS expectations – 2023e



— Carnegie
— Consensus

Source: Carnegie Research & FactSet

Adj. EPS expectations – 2024e



— Carnegie
— Consensus

Source: Carnegie Research & FactSet

Performance

snapshot	1M	3M	12M	YTD
Hansa Biopharma %	-3.3	-1.3	-54.2	-8.5
Peer group %	n.a.	n.a.	n.a.	n.a.
Carnegie Health Care %	-5.1	-3.7	21.1	11.1
OMXSPI %	-0.9	-2.0	6.6	6.1
MSCI Nordic %	-0.5	-2.3	9.0	5.3
MSCI Europe %	0.8	-1.5	10.7	8.6
S&P 500 %	3.3	9.8	14.5	18.1
MSCI World %	2.6	7.2	13.1	15.7

Source: FactSet

Valuation

snapshot	2022	2023e	2024e	2025e
P/E	n.m.	n.m.	n.m.	n.m.
P/E adj.	n.m.	n.m.	n.m.	n.m.
EV/EBITDA	neg.	neg.	neg.	neg.
EV/EBITA	neg.	neg.	neg.	neg.
P/BV	4.09	neg.	neg.	neg.
P/BV ex. GW	4.09	neg.	neg.	neg.
Dividend yield	0.0%	0.0%	0.0%	0.0%
FCF yield	-21.2%	-34.6%	-20.7%	-15.3%

Source: Carnegie Research

Hansa Biopharma
Carnegie estimates

	2022				2023							
SEKm	Q1	Q2	Q3	Q4	Q1	Q2	Q3e	Q4e	2021	2022	2023e	2024e
Revenues	30	26	67	31	24	37	48	64	34	154	173	381
Cogs	-11	-5	-18	-5	-10	-19	-10	-14	-15	-38	-51	-38
Gross profit	19	21	49	26	15	18	39	51	18	116	122	343
SG&A costs	-80	-90	-83	-82	-103	-129	-110	-125	-327	-336	-468	-477
R&D costs	-71	-93	-90	-92	-93	-115	-105	-115	-231	-346	-428	-470
Other income/expenses	-3	-6	-15	3	-1	-2	-3	-3	-7	-21	-9	-9
EBIT	-135	-168	-140	-145	-182	-228	-180	-193	-547	-587	-783	-614
Net financials	-3	-2	-14	-2	-23	-23	-2	-2	-1	-21	-48	-48
PTP	-138	-170	-154	-147	-205	-251	-181	-194	-548	-609	-832	-662
Tax	0	0	-1	-1	0	0	0	0	0	-1	0	146
Net profit	-138	-170	-154	-147	-205	-251	-181	-194	-548	-610	-832	-517
Revenue per segment												
Product sales	24	20	23	20	14	30	38	54	15	87	136	319
Licence income/other	6	7	44	10	10	7	10	10	19	68	37	62

Source: Company data and Carnegie Research

Valuation and risks

We rate Hansa BUY. Our recommendation is based on a sum-of-parts valuation. Based on our estimates, we arrive at a fair value of SEK109 (112). Please see our model assumptions and risks to our case below.

Project	Launch	Probability	Peak sales (USDm)	Valuation approach	NPV (SEKm)	NPV/peak sales	NPV/share (SEK)	Next catalyst
Idefirix (Kidney transplant, EU5)	2020	100%	81	DCF, WACC 10%	1,584	1.9	29	EU roll-out to accelerate H2(23)
Idefirix (Kidney transplant, US)	2026e	85%	127	DCF, WACC 10%	971	0.7	18	Complete Ph II/III randomization H2(23)
Idefirix (AMR)	2027e	50%	92	DCF, WACC 12%	358	0.4	7	Full Ph II data H2(23)
Idefirix (Anti-GBM)	2027e	70%	76	DCF, WACC 12%	362	0.5	7	Continued enrollment of Ph III H2(23)
Idefirix (GBS)	2028e	40%	336	DCF, WACC 12%	998	0.3	18	Ph II safety data H2(23), efficacy 2024
Idefirix - Sarepta Therapeutics (gene-therapy)	2027e	30%	124	DCF, WACC 12%	1,006	0.8	18	Start Ph I during 2023
Tech platform/line extensions (gene therapy, solid/cell tx)				Peer benchmark	1,000		18	Additional gene-therapy deals
Unallocated costs (21-24e)					-642		-12	
Enterprise Value (EV), SEKm					5,637			
Net Cash YE2022					734		13	Funded into 2025e
Return to NovaQuest on USD 70m principle					-350		-6	Repayments 24-28e with 2x Cap
Total NPV					6,020		109	

Source: Carnegie Research and company data

Assumptions

For Idefirix, we currently model total non-risk adjusted peak sales of USD836m across several different indications, including transplantation (highly sensitised kidney transplantation, AMR), rare autoimmune diseases (GBS and anti-GBM) and as an enabler for gene therapy in patients with neutralising antibodies. We model launch probabilities of 30–85% across indications in clinical development to reflect the risk of not reaching the market. To capture the uncertainty in commercial execution (penetration, pricing and reimbursement risks) and the risk of future competition, we discount future risk adjusted cash flows by a WACC of 10–12%. We have assigned a value of SEK1bn to the technology platform, including potential future use in gene therapy and the next generation IgG cleaving enzymes, based on a peer benchmark approach

Risks

Key risks include a failure to achieve adequate market access in key markets and a failure to gain approval for indications that are in clinical development. Until the company is cash-flow positive, it is dependent on external capital for funding. The current cash position should fund operations into 2025, according to the company. Idefirix is available under the conditional approval pathway in Europe, and full approval is conditional on good Phase III study results.

Carnegie's Sustainability Scorecard

Carnegie total ESG peer rating: 47%

Taxonomy eligible: No

Sustainability as a business driver

The pharmaceutical and biotechnology industry has transformed medicine and plays a crucial role in global health today. There is a strong connection between the health of patients, business, the workforce, communities, and the planet, and each of these affects one another. Sustainability in the pharma and biotech industry is defined by access to healthcare, environmental protection, ethics, and transparency. Hansa Biopharma strives to create sustainable value by developing drugs that can give people a better and longer life.


Sustainability targets and achievements

Hansa Biopharma's operations are conducted in compliance with regulatory guidelines and industry standards that naturally integrate many of the most important sustainability issues. The company's sustainability work focuses on conducting clinical development in compliance with ethical rules and guidelines, considering the environmental impact of both Hansa Biopharma's operations and those of its suppliers.

Sustainability related risks and past incidents

The pharmaceutical and biotechnology industry's main sustainability-related risks are related to access/affordability, ethics/social and environmental protection. The industry is highly regulated with laws and regulations on interactions with patients, healthcare professionals, society, customers, and business partners.

ESG rating – share of best peer score



Potential and incidents

Sust. driven growth	Fair
Past incidents	Insignificant

Exposure to negative impact industries

Fossil fuels	0%
Weapons	0%
Tobacco	0%
Pornography	0%
Alcohol	0%
Gambling	0%


Source tables and graph above: Carnegie Research

ESG Key Facts


Science-based CO2 reduction targets	No
Science-based CO2 neutrality target yr	na
Non-renewable energy cons. (%)	na
% women (board/senior exec/total)	33/17/60
Employee turnover rate (%)	8.7%
Absenteeism rate (%)	na
Accident frequency (per mill. hours)	na
Board meetings (number/attendance)	11/98%
Sustainability committee	No
Sust. performance in incentive prog.	Yes
Existence of a whistleblowing system	Yes
Taxonomy eligible revenue	na

Source: Carnegie Research & company data


Carbon emissions



Senior executives, % women



Compensation gap, CEO vs employees



Source: Carnegie Research & company data

Financial statements

Profit & loss	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Sales	3	3	3	3	6	34	154	173	381	608
COGS	0	0	-1	-1	-1	-15	-38	-51	-38	-61
Gross profit	2	3	2	3	5	18	116	122	343	547
Other income & costs	-112	-178	-247	-361	-425	-563	-700	-902	-954	-987
EBITDA	-110	-175	-245	-358	-420	-544	-584	-781	-611	-440
Depreciation PPE	2	2	2	2	1	1	1	1	1	1
Other amortisation	0	0	0	0	2	2	2	2	2	2
EBITA	-111	-176	-246	-360	-423	-547	-587	-783	-614	-443
GW amortisation & Impairment	0	0	0	0	0	0	0	0	0	0
EBIT	-111	-176	-246	-360	-423	-547	-587	-783	-614	-443
Net interest	0	-1	-2	0	2	-1	-21	-48	-48	-48
Other financial items	0	0	0	0	0	0	0	0	0	0
Share of earnings in ass. comp.	0	0	0	0	0	0	0	0	0	0
EAFI	-111	-177	-248	-360	-421	-548	-609	-832	-662	-491
Other EO items	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	-111	-177	-248	-360	-421	-548	-609	-832	-662	-491
Taxes	0	0	0	0	0	0	0	0	146	108
Post-tax minorities interest	0	0	0	0	0	0	0	0	0	0
Net profit	-111	-177	-248	-360	-421	-548	-609	-832	-517	-383
EO & Impairment adjustments	0	0	0	0	0	0	0	0	0	0
Tax on EO items	0	0	0	0	0	0	0	0	0	0
Adj.Net profit	-111	-177	-248	-360	-421	-548	-609	-832	-517	-383
Sales growth Y/Y	-61.4%	33.5%	-2.4%	0.0%	81.7%	455.6%	355.9%	11.9%	120.4%	59.6%
EBITA growth Y/Y	-chg	-chg	-chg	-chg	-chg	-chg	-chg	-chg	+chg	+chg
EBITDA margin	na	na	na	na	na	na	-378.3%	-451.4%	-160.4%	-72.3%
EBITA margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Tax rate	na	na	na	na	na	na	na	na	22.0%	22.0%
Cash flow	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
EBITDA	-110	-175	-245	-358	-420	-544	-584	-781	-611	-440
Net financial items	0	-1	-2	0	2	-1	-21	-48	-48	-48
Non cash adjustments	4	12	13	14	111	86	104	0	0	0
Change in NWC	12	13	29	10	17	-21	-21	-29	0	0
Paid taxes	0	0	0	0	0	0	0	0	146	108
Operating cash flow (OCF)	-95	-150	-205	-335	-290	-481	-523	-858	-514	-380
CAPEX PPE	-1	-2	-2	-3	0	-2	-3	0	0	0
CAPEX other intang. assets	0	0	0	-1	0	0	0	0	0	0
Net cash flow (NCF)	-96	-153	-207	-338	-291	-484	-526	-858	-514	-380
Other investments/Divestments	-45	5	-385	-9	0	0	0	0	-100	-150
Dividend paid	0	0	0	0	0	0	0	0	0	0
Share issues & buybacks	178	515	432	0	1,071	0	398	0	0	0
Other non-cash adjustments	0	0	0	-38	178	-4	-518	0	0	0
Change in LT non-IB liabilities	0	0	0	0	0	0	728	0	0	0
Decrease in net IB debt	37	368	-160	-385	958	-488	82	-858	-614	-530
Balance sheet	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Goodwill	0	0	0	0	0	0	0	0	0	0
Other fixed intangible assets	37	34	33	33	31	29	47	49	51	53
PPE	3	4	6	6	5	6	8	9	110	261
Shares & participations	0	0	0	0	0	0	0	0	0	0
Other fixed financial assets	15	19	40	9	5	35	28	28	28	28
Other fixed assets	0	0	0	0	0	0	0	0	0	0
Fixed assets	54	56	79	48	41	70	83	85	188	341
Inventories	0	0	0	0	0	0	1	30	30	30
Receivables	3	8	8	15	16	53	108	108	108	108
Other current assets	40	35	419	419	238	238	0	0	0	0
Cash & cash equivalents	214	581	439	182	1,139	651	1,496	611	-8	-807
Current assets	257	624	866	616	1,393	942	1,605	748	129	-669
Total assets	311	681	945	664	1,435	1,013	1,687	834	317	-328
Shareholders' equity	284	631	860	563	1,242	758	606	-226	-742	-1,125
Minorities	0	0	0	0	0	0	0	0	0	0
Sub-ordinated loans	0	0	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0	0	0
Deferred tax	1	1	1	1	0	0	0	0	0	0
Other IB & Non IB provisions	0	6	12	7	78	84	57	35	35	35
LT IB debt	1	0	0	0	0	0	763	763	763	500
LT non-IB liabilities	0	0	0	0	0	0	0	0	0	0
LT liabilities	1	6	13	8	78	84	820	798	798	535
ST IB debt	0	0	0	5	4	7	7	7	7	7
Payables	6	33	26	39	56	72	106	106	106	106
Other ST non-IB liabilities	19	11	46	51	54	92	148	148	148	148
Current liabilities	26	44	72	94	115	171	262	262	262	262
Total liabilities	311	680	945	664	1,434	1,013	1,687	834	317	-328

Source: Carnegie Research & company data

Share data & key ratios

Per share data (SEK)	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Adj. no. of shares in issue YE (m)	35.10	37.81	39.96	40.03	44.47	44.47	55.03	55.03	55.03	55.03
Diluted no. of Shares YE (m)	35.10	37.81	39.96	40.03	44.47	44.47	55.03	55.03	55.03	55.03
EPS	-3.29	-4.67	-6.38	-9.00	-9.96	-12.32	-12.23	-15.11	-9.39	-6.96
EPS adj.	-3.29	-4.67	-6.38	-9.00	-9.96	-12.32	-12.23	-15.11	-9.39	-6.96
CEPS	-3.29	-4.67	-6.38	-9.00	-9.96	-12.32	-12.23	-15.11	-9.39	-6.96
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
BVPS	8.08	16.7	21.5	14.1	27.9	17.0	11.0	-4.10	-13.49	-20.44
BVPS ex. GW	8.08	16.7	21.5	14.1	27.9	17.0	11.0	-4.10	-13.49	-20.44
NAVPS	8.08	16.7	21.5	14.1	27.9	17.0	11.0	-4.10	-13.49	-20.44
NIBDPS	-6.48	-15.84	-11.95	-4.51	-25.59	-14.63	-13.30	2.39	13.6	23.4
Valuation	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
P/E YE	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
P/E adj. YE	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
P/E average	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/E adj. average	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/CEPS YE	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/BV YE	14.41	14.96	12.86	5.96	8.61	5.21	4.47	neg.	neg.	neg.
P/BV ex. GW YE	14.41	14.96	12.86	5.96	8.61	5.21	4.47	neg.	neg.	neg.
Dividend yield YE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EV/EBIT YE	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
EV/EBITA YE	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
EV/EBITA adj. YE	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
EV/Sales YE	>50	>50	>50	>50	>50	>50	12.8	15.1	8.5	6.2
EV/EBITDA YE	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.	neg.
Share price YE	117	250	277	83.9	240	88.8	49.2	45.1		
Share price high	132	258	348	299	276	236	98.4	76.3		
Share price low	19.4	105	199	65.1	63.6	82.7	48.1	41.7		
Share price average	62.0	171	254	180	172	136	61.9	52.1		
Margins	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Gross margin	91.6%	93.6%	72.7%	74.5%	83.7%	54.5%	75.1%	70.3%	90.0%	90.0%
EBITDA margin	na	na	na	na	na	na	-378.3%	-451.4%	-160.4%	-72.3%
Adj. EBITDA margin	na	na	na	na	na	na	-378.3%	-451.4%	-160.4%	-72.3%
EBITA margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Adj. EBITA margin	na	na	na	na	na	na	-376.5%	-449.8%	-159.6%	-71.9%
Pre-tax margin	na	na	na	na	na	na	-393.9%	-480.9%	-173.8%	-80.7%
Net margin	na	na	na	na	na	na	-393.9%	-480.9%	-135.5%	-63.0%
Adj. net margin	na	na	na	na	na	na	-393.9%	-480.9%	-135.5%	-63.0%
Profitability	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
ROE	-44.9%	-38.6%	-33.3%	-50.6%	-46.6%	-54.8%	-89.3%	-437.4%	106.7%	41.0%
Adj. ROE	-44.9%	-38.6%	-33.3%	-50.6%	-46.6%	-54.8%	-89.3%	-437.4%	106.7%	41.0%
Adj. ROCE pre-tax	-44.7%	-38.2%	-32.7%	-49.5%	-44.0%	-50.4%	-53.3%	-82.7%	nm	188.8%
Adj. ROIC aft-tax	-283.6%	-701.0%	-1423.0%	-1982.8%	-7482.8%	-8887.3%	-1588.5%	-1065.2%	-338.3%	-127.2%
Adj. ROA pre-tax	-40.4%	-34.9%	-30.0%	-44.1%	-39.3%	-44.3%	-44.7%	-65.5%	-114.1%	8756.5%
FCF yield	-3.9%	-6.1%	-8.3%	-13.6%	-11.7%	-19.5%	-21.2%	-34.6%	-20.7%	-15.3%
Capital eff./Solv.	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Inventories / Sales	0.0%	0.0%	0.0%	0.0%	1.6%	0.7%	0.6%	17.4%	7.9%	4.9%
Receivables / Sales	132.0%	235.9%	239.1%	436.4%	258.8%	156.8%	69.6%	62.2%	28.2%	17.7%
Payables / Sales	251.3%	945.4%	780.2%	1151.6%	924.9%	213.9%	68.9%	61.5%	27.9%	17.5%
NWC / Sales	-28.4%	-399.4%	-634.2%	-628.2%	-529.1%	-88.0%	-5.5%	9.6%	8.2%	5.1%
Asset turnover	0.01	0.01	0.00	0.00	0.01	0.03	0.11	0.14	0.66	-109.70
Sales / Capital invested	0.07	0.14	0.20	0.19	1.09	5.56	4.22	2.37	2.72	2.27
OCF / Capex	-96.10	-68.23	-86.46	-124.00	-987.41	-200.58	-165.60	nm	nm	nm
Capex / Sales	38.2%	63.9%	70.5%	80.4%	4.8%	7.1%	2.0%	0.0%	0.0%	0.0%
Capex / Depreciation PPE	-0.63	-1.41	-1.52	-1.74	-0.37	-3.00	-3.95	0.00	0.00	0.00
Dividend payout ratio	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Equity / Total assets	91%	93%	91%	85%	87%	75%	36%	-27%	-234%	343%
Net IB debt / Equity	-80%	-95%	-56%	-32%	-92%	-86%	-121%	-58%	-101%	-114%
Net IB debt / EBITDA	2.1	3.4	2.0	0.5	2.7	1.2	1.3	-0.2	-1.2	-2.9
EBITDA / Net interest	n.m.	n.m.	n.m.	4712.1	217.2	n.m.	n.m.	n.m.	n.m.	n.m.
EBITA / Net interest	n.m.	n.m.	n.m.	4732.6	218.6	n.m.	n.m.	n.m.	n.m.	n.m.
Balance sheet data	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Net IB debt	-228	-599	-478	-181	-1,138	-651	-732	131	751	1,286
Net working capital (NWC)	-3	-24	-18	-24	-41	-19	2	31	31	31
Capital employed (CE)	285	637	873	575	1,324	848	1,433	579	63	-583
Capital invested (CI)	36	13	21	15	-4	16	57	89	192	344
Enterprise value YE (EV)	3,862	8,834	10,583	3,176	9,553	3,299	1,977	2,611	3,230	3,766

Source: Carnegie Research & company data

Disclosures and disclaimers

Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries.

Ratings and risk assessment structure

Current rating system as of October 2011

Buy (B), upside of at least 10% to the target price and with an attractive risk/reward profile

Hold (H), neutral risk/reward profile or the stock is trading relatively near its target price

Sell (S), unattractive risk/reward profile and the stock is trading above its target price

Not rated (NR), Under review (UR), Under bid (UB). The investment rating, if any, has been suspended temporarily.

Ratings may from time to time deviate from the definitions above owing to market volatility. Any such deviation will be assessed regularly to determine whether it should no longer be considered temporary.

Risk assessment

The risk assessment is based on the analyst's evaluation of the company's equity beta based on the business risk (asset beta) and financial risk (gearing).

Low risk estimated equity beta <0.75

Medium risk estimated equity beta 0.75 to 1.25

High risk estimated equity beta >1.25

Valuation, methodology, and assumptions

Target price

Carnegie publishes a target price for most of the stocks in our Research Universe. The target price is the analyst's assessment of expected total return over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers to obtain a target price. For companies where it is appropriate, a target price can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Target prices are revised when earnings and cash flow forecasts are changed. Thus, changes to estimates are a key risk to the target price. Other reasons for revising target prices include changes in the underlying value of a company's assets and when factors affecting the required rate of return change, which can also be seen as risk factors to the target price.

Information

You will find detailed information about the valuation or methodology, the underlying assumptions and risks on Carnegie Edge (www.carnegie-edge.com). The complete history of research reports and previous recommendations can also be found on Carnegie Edge.

Research coverage

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Analyst certification

The research analyst or analysts responsible for the content of this report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this report.

Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by arrangements (Chinese walls) to restrict the flows of sensitive information. Persons outside a Chinese wall may gain access to sensitive information only after having observed applicable Chinese wall crossing procedures. The remuneration of persons involved in preparing this report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

Research Disclaimer

Carnegie Investment Bank AB is responsible for the preparation of this research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this research report in Norway. Carnegie Inc. is responsible for this research report in the US.

The information in this report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading, Carnegie does not guarantee its accuracy or completeness. If the report has been disclosed to the issuer and amended following this disclosure before its dissemination, it will be referred to in the company-specific disclosures. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

This research report is prepared for general circulation and general information only. It does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this report or its contents. This report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to physical or legal entities that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.


Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). This report is distributed in Sweden by Carnegie Investment Bank AB. This report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie Investment Bank AB. Carnegie UK is authorised and regulated by the Financial Conduct Authority (FCA).

In Finland this report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finanssivalvonta). In Norway this report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet).

In Denmark this report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet). This report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie analysts located outside of the United States are employed by non-US affiliates that are not subject to FINRA regulations. This report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Any US person who wishes to effect transactions based on this report should contact Carnegie Inc. Investors in the US should be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, nor be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission.

Hansa Biopharma price, rating and target price history – 3y (HNSA.ST)

Date	Rating	Target Price
21 Apr 2023	Buy	SEK 112.0
18 Jan 2023	Buy	SEK 128.0
19 Jul 2022	Buy	SEK 121.0
11 Jan 2022	Buy	SEK 120.0
06 Oct 2021	Hold	SEK 140.0
22 Apr 2021	Hold	SEK 190.0
22 Nov 2020	Sell	SEK 190.0



Our **Target Price Horizon** is 6–12 months

Source: Carnegie Research & FactSet

Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the subject company.

Within the past 12 months Carnegie (refer to definition in disclaimer text) has received compensation for investment banking services regarding Agilyx, Airthings, Atlantic Sapphire, BerGenBio, Catena Media, Cloudberry Clean Energy, Duell Corporation, F-Secure, Irras, Karnov, Kongsberg Gruppen, Meltwater, Navamedic, NEL, Nordic Nanovector, Norsk Titanium, Norske Skog, Otovo, PGS, Prosafe, Rejlers, SalMar, Sleep Cycle, Topdanmark and VEF.

Within the past 12 months Carnegie (refer to definition in disclaimer text) has managed or co-managed a public offering of securities of BHG, Cantargia, CTEK, Egetis Therapeutics, Ferroamp, Genova, Irras, Nimbus Group, Ovzon, Q-linea, Securitas, Smart Eye, Storskogen, TF Bank, Trianon, Vicore Pharma, Vimian and VNV Global.

Please see Carnegie AS' website for a full list of shares owned by employees of Carnegie AS in relation to potential conflicts of interest: www.carnegie.no (General business terms and more / Employees holdings). Carnegie AS may also own shares in connection with trading. This disclosure is made to meet Norwegian best practice.

A Board member of Carnegie Investment Bank AB (who is not an analyst) is a member of the Board of Directors of Kinnevik. Carnegie Investment Bank AB acts as a market maker in the Vimian share. Carnegie Investment Bank AB acts as a market maker in the Sagax share. Carnegie Investment Bank AB acts as a market maker in the Fastpartner share. Carnegie Investment Bank AB acts as a market maker in the Kindred share. Carnegie Investment Bank AB acts as a market maker in the Solar share. Carnegie Investment Bank AB acts as a market maker in the TF Bank share. Carnegie Investment Bank AB acts as a market maker in the Devyser share. Carnegie Investment Bank AB acts as a market maker in the RugVista share.

Stock rating distribution in the previous 12 months

Ratings	Carnegie coverage universe % of total	Investment banking services* % of total
Buy	57	69
Hold	37	31
Sell	5	0

*Investment banking services provided by Carnegie in the previous 12 months

Copyright © 2023 Carnegie



Hansa Biopharma Company Summary

21 July 2023

Profit & loss	2021	2022	2023e	2024e	2025e
Sales	34	154	173	381	608
EBITDA	-544	-584	-781	-611	-440
EBITA	-547	-587	-783	-614	-443
EBIT	-547	-587	-783	-614	-443
Pre-tax profit	-548	-609	-832	-662	-491
Net profit	-548	-609	-832	-517	-383
Adj. net profit	-548	-609	-832	-517	-383

Balance sheet	2021	2022	2023e	2024e	2025e
Total assets	1,013	1,687	834	317	-328
Shareholders' equity	758	606	-226	-742	-1,125
Goodwill	0	0	0	0	0
Net IB debt	-651	-732	131	751	1,286

Cash flow	2021	2022	2023e	2024e	2025e
EBITDA	-544	-584	-781	-611	-440
Operating cash flow	-481	-523	-858	-514	-380
Net cash flow (NCF)	-484	-526	-858	-514	-380
Decrease in net IB debt	-488	82	-858	-614	-530

Per share data	2021	2022	2023e	2024e	2025e
EPS	-12.32	-12.23	-15.11	-9.39	-6.96
EPS adj.	-12.32	-12.23	-15.11	-9.39	-6.96
EPS adj. Growth	-chg	+chg	-chg	+chg	+chg
CEPS	-12.32	-12.23	-15.11	-9.39	-6.96
DPS	0.00	0.00	0.00	0.00	0.00
BVPS ex. GW	17.0	11.0	-4.10	-13.49	-20.44
NIBDPS	-14.63	-13.30	2.39	13.6	23.4

Ratios	2021	2022	2023e	2024e	2025e
P/E	nm	nm	nm	nm	nm
P/E adj.	nm	nm	nm	nm	nm
P/BVPS	2.6	4.1	neg.	neg.	neg.
P/BVPS ex. GW	2.6	4.1	neg.	neg.	neg.
P/CEPS	neg.	neg.	neg.	neg.	neg.
EV/Sales	>50	11.31	15.10	8.48	6.19
EV/EBITDA	neg.	neg.	neg.	neg.	neg.
EV/EBITA	neg.	neg.	neg.	neg.	neg.
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%
FCF yield	-19.5%	-21.2%	-34.6%	-20.7%	-15.3%

Company description

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG) mediated autoimmune conditions, transplant rejection and cancer. Idefixir received conditional approval in Europe in 2020 for kidney transplantation in highly sensitised patients and is being developed for use in other indications including rare acute autoimmune indications. Hansa is also developing the next generation of IgG-cleaving enzymes, with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden, and also has operations in other European countries and in the US.

Company miscellaneous

CEO Søren Tulstrup	Scheelevägen 22, Lund
CFO Donato Spota	+46 46 16 56 70
IR Klaus Sindahl	www.hansamedical.com

Major shareholders

	Capital	Votes		Capital	Votes
Redmile group LLC	13.0%	13.0%	Nextobe AB	4.8%	4.8%
Handelsbanken fonder	5.1%	5.1%	Invesco	4.4%	4.4%
AP 4	4.9%	4.9%	Olausson, Thomas	4.1%	4.1%

Carnegie Investment Bank AB

Tel +46 8 676 88 00 Fax +46 8 676 88 95

Carnegie AS

Tel +47 22 00 93 00 Fax +47 22 00 94 00

Carnegie Investment Bank, Denmark Branch

Tel +45 32 88 02 00 Fax +45 32 96 10 22

Carnegie, Inc.

Tel +1 212 262 5800 Fax +1 212 265 3946

Carnegie Investment Bank AB, Finland Branch

Tel +358 9 618 71 230 Fax +358 9 618 71 720

Carnegie Investment Bank AB, UK Branch

Tel +44 20 7216 4000 Fax +44 20 7417 9426

Sources this page: Carnegie Research & company data